Barda Will Implement a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2 Trial in the US to Evaluate the Safety and Efficacy of Novel Host-Directed Therapeutic Candidates in Hospitalized Adults With Ards
Contract Overview
Contract Amount: $117,399,278 ($117.4M)
Contractor: PPD Development LP
Awarding Agency: Department of Health and Human Services
Start Date: 2023-12-15
End Date: 2030-09-30
Contract Duration: 2,481 days
Daily Burn Rate: $47.3K/day
Official Description: BARDA WILL IMPLEMENT A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2 TRIAL IN THE US TO EVALUATE THE SAFETY AND EFFICACY OF NOVEL HOST-DIRECTED THERAPEUTIC CANDIDATES IN HOSPITALIZED ADULTS WITH ARDS.
Place of Performance
Location: North Carolina, 28401